Business Wire

Statens Serum Institut Large Danish Study Finds No Link Between Vaccines and Autism or 49 Other Health Conditions

15.7.2025 13:00:00 CEST | Business Wire | Press Release

Share

A new Danish study finds no association between aluminum in childhood vaccines and 50 different health conditions, including autism, asthma, and autoimmune diseases. The findings reaffirm the safety of Denmark’s childhood vaccination program.

An extensive new Danish register-based study - the largest of its kind - supports the safety of the national childhood immunization program. Analyzing data from over 1 million children, the study found no increased risk of autism, asthma, or autoimmune diseases in vaccinated children.

“Our results are reassuring. By analyzing data from more than one million Danish children, we found absolutely no indication that the very small amount of aluminum used in the childhood vaccination program increases the risk of 50 different health outcomes during childhood,” says Anders Hviid, Head of Department at Statens Serum Institut (SSI) and principal investigator on the study.

Aluminum, used as an adjuvant to enhance the immune response, has been a component in some vaccines since the 1930s.

Researchers from SSI used Denmark’s unique national health registers to follow children born between 1997 and 2018, investigating the associations between aluminum-containing vaccines and a total of 50 health outcomes - including asthma, allergies, autoimmune conditions, and neurodevelopmental disorders.

“This is the first study of this scale and with such comprehensive analyses, and it confirms the strong safety profile of the vaccines we’ve used for decades in Denmark,” says Anders Hviid.

The results are being published at a time of heightened international debate about vaccine safety which makes the Danish study highly relevant.

“In an era marked by widespread misinformation about vaccines, it is crucial to rely on solid scientific evidence. Large, population-based register studies like this one - tracking more than a million children over many years - are a bulwark against the politicization of health science which undermines public trust in vaccines. It is absolutely essential to distinguish real science from politically motivated campaigns - otherwise, it is the children who will end up paying the price,” says Anders Hviid.

Reference:

Andersson NW, Bech Svalgaard I, Hoffmann SS, et al. Aluminum-adsorbed vaccines and chronic diseases in childhood. A nationwide cohort study.Ann Intern Med. 15 July 2025. [Epub ahead of print]. doi:10.7326/ANNALS-25-00997

Fact Box:

  • Researchers from Statens Serum Institut (SSI) used Denmark’s unique health registers to analyze data from more than 1 million Danish children born between 1997 and 2018 to investigate potential long-term health effects of aluminum-containing vaccines.
  • The study examined 50 different conditions and found no statistical association between aluminum content in vaccines and increased risk of developing autism, autoimmune diseases, asthma, or allergic conditions such as hay fever and food allergies.
  • The study has just been published in the prestigious medical journal Annals of Internal Medicine.
    Source: Statens Serum Institut (SSI)

View source version on businesswire.com: https://www.businesswire.com/news/home/20250714416158/en/

Contacts

Anders Hviid, aii@ssi.dk

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye